These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 22514189)

  • 21. Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register.
    Kristensen LE; Karlsson JA; Englund M; Petersson IF; Saxne T; Geborek P
    Arthritis Care Res (Hoboken); 2010 Oct; 62(10):1362-9. PubMed ID: 20506310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis.
    Savioli C; Ribeiro AC; Fabri GM; Calich AL; Carvalho J; Silva CA; Viana VS; Bonfá E; Siqueira JT
    J Clin Rheumatol; 2012 Jun; 18(4):180-4. PubMed ID: 22647860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine.
    Gremese E; Carletto A; Padovan M; Atzeni F; Raffeiner B; Giardina AR; Favalli EG; Erre GL; Gorla R; Galeazzi M; Foti R; Cantini F; Salvarani C; Olivieri I; Lapadula G; Ferraccioli G;
    Arthritis Care Res (Hoboken); 2013 Jan; 65(1):94-100. PubMed ID: 22730143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TNFalpha therapy in psoriatic arthritis and psoriasis.
    Mease P
    Ann Rheum Dis; 2004 Jul; 63(7):755-8. PubMed ID: 15194567
    [No Abstract]   [Full Text] [Related]  

  • 25. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data.
    Coates LC; Helliwell PS
    Arthritis Care Res (Hoboken); 2010 Jul; 62(7):965-9. PubMed ID: 20589696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M; Wirthmüller U; Möller B; Villiger PM
    Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial.
    Karanikolas GN; Koukli EM; Katsalira A; Arida A; Petrou D; Komninou E; Fragiadaki K; Zacharioudaki A; Lasithiotakis I; Giavri E; Vaiopoulos G; Sfikakis PP
    J Rheumatol; 2011 Nov; 38(11):2466-74. PubMed ID: 21885499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Minimal disease activity and anti-tumor necrosis factor therapy in psoriatic arthritis.
    Haddad A; Thavaneswaran A; Ruiz-Arruza I; Pellett F; Chandran V; Cook RJ; Gladman DD
    Arthritis Care Res (Hoboken); 2015 May; 67(6):842-7. PubMed ID: 25469741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity.
    Krieckaert CL; Jamnitski A; Nurmohamed MT; Kostense PJ; Boers M; Wolbink G
    Arthritis Rheum; 2012 Dec; 64(12):3850-5. PubMed ID: 22933315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register.
    Kristensen LE; Gülfe A; Saxne T; Geborek P
    Ann Rheum Dis; 2008 Mar; 67(3):364-9. PubMed ID: 17644547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.
    Mancarella L; Bobbio-Pallavicini F; Ceccarelli F; Falappone PC; Ferrante A; Malesci D; Massara A; Nacci F; Secchi ME; Manganelli S; Salaffi F; Bambara ML; Bombardieri S; Cutolo M; Ferri C; Galeazzi M; Gerli R; Giacomelli R; Grassi W; Lapadula G; Cerinic MM; Montecucco C; Trotta F; Triolo G; Valentini G; Valesini G; Ferraccioli GF;
    J Rheumatol; 2007 Aug; 34(8):1670-3. PubMed ID: 17611987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The role of biological agents in the treatment of psoriatic arthritis, literature review].
    Koó E; Brodszky V; Péntek M; Ujfalussy I; Nagy MB; Gulácsi L
    Orv Hetil; 2006 Oct; 147(41):1963-70. PubMed ID: 17120686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
    Saougou I; Markatseli TE; Papagoras C; Voulgari PV; Alamanos Y; Drosos AA
    Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor-α blockers in psoriatic arthritis: a longitudinal study with 6 months of followup.
    Ramírez J; Fernández-Sueiro JL; López-Mejías R; Montilla C; Arias M; Moll C; Alsina M; Sanmarti R; Lozano F; Cañete JD
    J Rheumatol; 2012 May; 39(5):1035-41. PubMed ID: 22467926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of anti-TNF therapy on glucose metabolism in patients with ankylosing spondylitis, psoriatic arthritis or juvenile idiopathic arthritis.
    da Silva BS; Bonfá E; de Moraes JC; Saad CG; Ribeiro AC; Gonçalves CR; de Carvalho JF
    Biologicals; 2010 Sep; 38(5):567-9. PubMed ID: 20638299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thalassemic trait prevalence in patients affected by psoriatic arthritis in anti-TNF treatment.
    Atteno M; Costa L; Vitiello M; Caso F; Sarnelli G; Del Puente A; Scarpa R
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S20-2. PubMed ID: 25381968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.
    Fernández-Nebro A; Tomero E; Ortiz-Santamaría V; Castro MC; Olivé A; de Haro M; Portales RG; González-Mari MV; Laffón A; García-Vicuña R
    Am J Med; 2005 May; 118(5):552-6. PubMed ID: 15866260
    [No Abstract]   [Full Text] [Related]  

  • 38. Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT.
    Mease PJ; Heckaman M; Kary S; Kupper H
    J Rheumatol; 2013 May; 40(5):647-52. PubMed ID: 23504383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?
    Otten MH; Prince FH; Ten Cate R; van Rossum MA; Twilt M; Hoppenreijs EP; Koopman-Keemink Y; Oranje AP; de Waard-van der Spek FB; Gorter SL; Armbrust W; Dolman KM; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2011 Feb; 70(2):337-40. PubMed ID: 21068101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
    Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.